公开(公告)号：WO2021245107A2

公开(公告)日：2021-12-09

申请号：PCT/EP2021/064718

申请日：2021-06-01

申请人： INSTITUT GUSTAVE ROUSSY

发明人： PERFETTINI, Jean-Luc ,  LECUYER, Deborah ,  TANNOUS, Désirée ,  ALLOUCH, Awatef ,  DELELIS, Olivier ,  SUBRA, Frederic

IPC分类号： A61K31/7084 ,  A61K31/675 ,  A61K31/7072 ,  A61P11/00 ,  A61P31/14 ,  A61K45/06

摘要： The inventors herein show that purinergic receptors regulate the conversion of macrophage pro-inflammatory reprogramming into anti-inflammatory phenotype in patients suffering from COVID-19 disease. Moreover, they show that P2Y receptor agonists repress NLRP3 inflammasome-dependent IL-1b secretion, but also impair the replication and the cytopathogenic effects of SARS-CoV-2. These results therefore suggest that some purinergic receptors agonists can treat acute lung injury and respiratory disease that are associated with SARS-CoV-2 infection. In addition, their results show that antagonists of the purinergic receptors P2X impair the replication of said virus. The present invention therefore proposes to use purinergic receptors modulators and NLR3-P2Y2R immune checkpoint modulators to treat patients suffering from a virus-induced acute respiratory distress syndrome.